Cardiolipin Antibodies

Blood clots are supposed to form only when you are injured. But in some people, the immune system produces antibodies that trick the clotting system into activating without a wound. These antibodies target cardiolipin, a fat molecule embedded in cell membranes throughout the body. When present at meaningful levels, they raise the risk of clots in veins and arteries, strokes, heart attacks, and pregnancy loss. A single antibody test can flag this risk, but measuring all three antibody classes together reveals which arm of the immune response is involved and how seriously to take the finding.

This panel measures three classes of antibodies against cardiolipin: Immunoglobulin G (IgG), Immunoglobulin M (IgM), and Immunoglobulin A (IgA). Each class reflects a different phase or pathway of the immune response. IgG and IgM are part of the established criteria for diagnosing antiphospholipid syndrome (APS), a condition in which the immune system drives dangerous clotting. IgA is not yet part of formal diagnostic criteria but emerging evidence ties it to clotting risk, especially in people whose IgG and IgM come back normal.

What This Panel Reveals

Cardiolipin is a phospholipid, a type of fat that sits in the membranes of cells. When the immune system mistakenly makes antibodies against it, those antibodies can bind to proteins on blood vessel walls and platelets (the small blood cells involved in clotting), pushing the clotting system into overdrive. The result is a higher chance of forming clots where none should exist.

IgG antibodies represent the mature, sustained immune response. Among the three antibody classes, IgG anticardiolipin antibodies show the strongest and most consistent association with blood clots. In the Euro-Phospholipid Project, a large multicenter study following 1,000 patients with antiphospholipid syndrome, venous clots (deep vein thrombosis and pulmonary embolism) occurred in about 38.9% of the cohort, and arterial events including stroke occurred in about 19.8%. IgG positivity, particularly at medium to high titers, or measured concentration levels (above 40 GPL units, the standard scale for this antibody), carried the greatest predictive weight.

IgM antibodies are the first responders of the immune system. They appear early in an immune reaction and sometimes fade over time. A positive IgM with a negative IgG may reflect a new or temporary immune response rather than a persistent autoimmune condition. However, persistently positive IgM results, confirmed on retesting at least 12 weeks later, still count toward a diagnosis of antiphospholipid syndrome under the revised classification criteria.

IgA antibodies occupy an emerging role. They are not included in the current international classification criteria for antiphospholipid syndrome, but multiple studies have found that isolated IgA positivity (meaning IgG and IgM are negative) can still be associated with clotting events. IgA testing adds a layer of detection that standard two-antibody panels miss.

How to Read Your Results Together

The real value of this panel comes from the pattern across all three antibody classes, not from any single result. A single positive result in isolation means something very different from two or three positives together.

Titer (the measured concentration of antibodies in your blood) matters as much as positivity. Low-positive results (just above the cutoff) are far less predictive of clotting than medium or high titers. The revised Sapporo classification criteria specifically require medium to high titers of IgG or IgM (above 40 GPL or MPL units, the standard measurement scales, or above the 99th percentile for the laboratory) on at least two occasions 12 or more weeks apart.

When Results Can Be Misleading

Several situations can produce a temporarily positive cardiolipin antibody result without reflecting true autoimmune disease. Infections are the most common cause. Viral infections (including COVID-19, hepatitis C, and Epstein-Barr virus), bacterial infections, and even some medications can trigger short-lived anticardiolipin antibodies that disappear once the infection clears.

Syphilis testing deserves a specific mention. The RPR and VDRL, standard blood tests used to screen for syphilis, can cross-react with cardiolipin antibodies, and conversely, anticardiolipin antibodies can cause false-positive syphilis screening results. If you test positive for cardiolipin antibodies, your doctor may want to rule out syphilis, and vice versa.

Age also plays a role. Low-titer anticardiolipin antibodies become more common with aging. Population studies have found that a meaningful percentage of healthy older adults may have low-positive anticardiolipin antibodies without any history of clotting. This is why titer level and confirmation testing matter so much.

Tracking Over Time

A single positive result on this panel is not a diagnosis. The international classification criteria require confirmation at least 12 weeks after the first positive test, because temporary positivity is common. This built-in requirement for repeat testing makes serial tracking essential, not optional.

For people with confirmed persistent positivity, repeat testing every 6 to 12 months helps track whether antibody levels are rising, stable, or declining. Rising titers may signal increased risk and could prompt a conversation about preventive blood thinning. Declining titers, while not a guarantee of safety, can be reassuring. In people on blood-thinning therapy for confirmed antiphospholipid syndrome, antibody levels help guide decisions about how long to continue treatment.

If you have a first-degree relative with antiphospholipid syndrome or lupus, or if you have had an unexplained blood clot or pregnancy loss, annual screening with this panel provides early detection of an immune process that can be managed before it causes harm.

What to Do with Your Results

If all three antibody classes come back negative, your immune system is not currently producing detectable antibodies against cardiolipin. No further action is needed unless your clinical suspicion remains high, in which case beta-2 glycoprotein I antibodies and lupus anticoagulant testing can catch antiphospholipid activity that cardiolipin antibodies alone may miss.

If one or more results are positive, the immediate next step is confirmation testing in 12 weeks. Do not start treatment based on a single positive result. While waiting for confirmation, discuss your clotting risk factors (smoking, oral contraceptives, immobility, recent surgery) with a physician, since these multiply the risk that antiphospholipid antibodies create.

For confirmed persistent positivity, a referral to a rheumatologist (autoimmune disease specialist) or hematologist (blood disorder specialist) is appropriate. The specialist will assess whether you meet criteria for antiphospholipid syndrome and whether preventive blood-thinning treatment (typically low-dose aspirin or, in higher-risk profiles, warfarin) is warranted. If you are planning pregnancy and have confirmed anticardiolipin antibodies, early involvement of a maternal-fetal medicine specialist can significantly reduce the risk of pregnancy complications.